In line / mixed
Growth was strong across cardiovascular and med-surgical businesses, with FARAPULSE and WATCHMAN again central.
[AS-EXP-028]Boston Scientific
Q2 2025: A broad beat and a guidance increase larger than the quarterly surprise reinforced estimate momentum.
ResultIn line / mixedGuidanceRaisedEnvironmentimproving
Investment snapshot
What happened and why it mattered
Raised
Management raised the annual outlook by more than twice the quarterly dollar beat, implying confidence in the second half.
[AS-EXP-028]No clear inflection
Management raised the annual outlook by more than twice the quarterly dollar beat, implying confidence in the second half.
[AS-EXP-028]Qualitative
The stock moved only modestly because positioning was crowded and a high-quality quarter was already expected.
[AS-ME-084]Results versus expectations
The print and the three most important read-throughs
Growth was strong across cardiovascular and med-surgical businesses, with FARAPULSE and WATCHMAN again central.
- 1
Growth was strong across cardiovascular and med-surgical businesses, with FARAPULSE and WATCHMAN again central.
Guidance bridge
GuidanceRaisedLatest outlook and KPI implications
Management raised the annual outlook by more than twice the quarterly dollar beat, implying confidence in the second half.
| Metric | Prior | Latest | Consensus | Delta | Status | Reason / implication |
|---|---|---|---|---|---|---|
| FY reported net sales growth | 15%–17% | 18%–19% | ~16.4% (Street) | +250 bps midpoint | Updated | Broad global momentum, M&A, FX tailwind |
| FY organic net sales growth | 12%–14% | 14%–15% | ~13.7% | +150 bps midpoint | Updated | Cardiology/EP + WATCHMAN momentum |
| FY GAAP EPS | $1.86–$1.93 | $1.89–$1.93 | NOT AVAILABLE | +raised low end | Raised | Sales drop-through, offset by ACURATE charges |
| FY adjusted EPS | $2.87–$2.94 | $2.95–$2.99 | $2.92 | +6–6.5c midpoint (~2%) | Updated | Drop-through, spend control, lower tariffs |
| FY adj. operating margin expansion | +50–75 bps | +75–100 bps | ~+80 bps (RBC model) | +25 bps | Updated | Strong 1H margin performance |
| FY adj. gross margin | Roughly in line w/ 2024 | Roughly in line w/ 2024 | ~70.3% (RBC) | No change | Maintained | Mix (FARAPULSE/WATCHMAN) offsets ACURATE + tariff |
Management signal — paraphrased
Management raised the annual outlook by more than twice the quarterly dollar beat, implying confidence in the second half.
Implied cadence
Management raised the annual outlook by more than twice the quarterly dollar beat, implying confidence in the second half.
Stock reaction
Why the shares moved
The stock moved only modestly because positioning was crowded and a high-quality quarter was already expected.
- The stock moved only modestly because positioning was crowded and a high-quality quarter was already expected.
Did the reaction persist?
[AS-ME-084]Not independently calculated in the compact record.
Adjusted-close reaction
Independent return windows were not embedded in this compact record. The reaction assessment is qualitative.
Source-reported qualitative reaction; no independent price series embeddedMarket environment delta
EnvironmentimprovingWhat management said about the operating backdrop
A broad beat and a guidance increase larger than the quarterly surprise reinforced estimate momentum.
- Customer demand (AFib referrals, procedure demand)Improving
Underlying EP market growth "nearly 20% right now," largest, fastest-growing market in medtech
OutlookManagement expects mid-teens market growth to persist as it slows from ~20%KPI implicationSupports 14–15% FY organic guideManagement interpretation · Medium confidence · [137] - Volumes / procedures (PFA penetration, WATCHMAN concomitant)Improving
WATCHMAN +28% WW / ~30% US; 60% of WATCHMAN-implanting EPs now doing concomitant
OutlookCategory could grow "plus 20% range" as it scalesKPI implicationWATCHMAN $486M, +28% organicDisclosed fact · High confidence · [138] - Regional / end-market (China, Japan, APAC, EM)Improving
US +31%; APAC +15.4% op; Japan high-teens (clear PFA leader, 15k patients); China mid-teens; EM +12.1%
OutlookJapan persistent label in 2H a tailwind; China "very early days," gradual provincial rampKPI implicationBroad-based regional beat underpinning guide raiseDisclosed fact · High confidence · [142]
- Channel / inventory (ACURATE withdrawal charge)Worsening
~$100M adjusted inventory/sales-return charge + ~$130M GAAP; majority inventory write-off
OutlookNo material 2H25 operating-margin impact; ~800bps 2H ICTx growth headwindKPI implication~130–135bps Q2 adj GM dragDisclosed fact · High confidence · [139] - Supply availabilityStable
Supply chain conditions continued to improve, though some raw-material cost/availability constraints persist
OutlookOngoing US and OUS capacity expansion to meet demandKPI implicationNo disclosed supply-driven revenue constraintDisclosed fact · Medium confidence · [140] - Input costs / labor / margins (lab capacity, tariffs)Improving
Tariff halved to ~$100M; FY adj GM held flat; OM expansion raised to 75–100bps
OutlookMix (FARAPULSE/WATCHMAN) bridges tariff + ACURATE to flat GMKPI implicationAdj OM 27.6%, +50bps; FY OM +75–100bpsDisclosed fact · High confidence · [141]
- Competition (FARAPULSE vs Affera/Sphere-9, Varipulse, Volt)Stable
BSX aims to be "clear PFA leader" and #1 in EP; #2 global EP share achieved; competitive market "for many years to come"
OutlookVolt (ABT) launch early 2026 the key watch item; BSX leans on ecosystem (mapping, ICE, access)KPI implicationEP $840M, +93.7% organic; ~20% global EP shareManagement interpretation · Medium confidence · [135] - Pricing (China VBP, ASPs)Stable
China returned to mid-teens growth; net price ~flat, mix the main margin lever
OutlookVBP participation expands access; BSX expects mid-teens China growth to continue in 2HKPI implicationLow-single-digit drug-eluting growth from China VBP participationDisclosed fact · Medium confidence · [136]
Evidence and confidence
Source map
No material gap recorded.
AlphaSense synthesis
Open source ↗Official company source
Open source ↗AlphaSense market-environment synthesis
Open source ↗